Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Bone Remodeling01:40

Bone Remodeling

Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex-based differences in tolerability of developmental antibody-drug conjugates (ADCs) in non-small-cell lung cancer (NSCLC).

ESMO open·2026
Same author

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

British journal of cancer·2026
Same author

Corrigendum to 'Subcutaneous versus intravenous nivolumab for renal cell carcinoma': [Annals of Oncology volume 36 (2025) 99-107].

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Novel and bone-targeted agents for CRPC.

K Fizazi1, L Albiges, C Massard

  • 1Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif 94800, France. karim.fizazi@igr.fr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|September 19, 2012
PubMed
Summary
This summary is machine-generated.

Recent advancements have yielded numerous new treatments for castration-resistant prostate cancer (CRPC). These emerging therapies are significantly improving survival, offering new hope for patients with advanced prostate cancer.

More Related Videos

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Related Experiment Videos

Last Updated: May 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Prostate cancer has seen remarkable therapeutic breakthroughs since 2010, particularly in castration-resistant prostate cancer (CRPC).
  • Until recently, docetaxel was the sole survival-improving agent for metastatic CRPC.

Framework:

  • Exceptional progress in the last two years with multiple agents demonstrating positive Phase III trial outcomes.
  • Key approved agents include sipuleucel-T, cabazitaxel, denosumab, abiraterone, radium-223, and enzalutamide.
  • Ongoing research includes promising agents like orteronel, ipilimumab, and cabozantinib.

Implementation:

  • These novel agents are poised to transform the routine management of CRPC.
  • Median life expectancy for CRPC patients is projected to increase from approximately 1 year to over 30 months.

Implications:

  • New challenges arise concerning treatment cost, optimal sequencing or combination strategies, and personalized medicine based on disease biology.
  • Future drug development must account for the confounding effects of multiple approved agents on overall survival.